Isavuconazole for the treatment of fungal infections: a real-life experience from the Fungal Infection Network of Switzerland (FUNGINOS)

Abstract This analysis of 116 isavuconazole therapy courses shows that hepatic test disturbances (HTD) were relatively frequent (29% cases), but rarely led to treatment interruption (5%). Importantly, patients with baseline HTD, including those attributed to a first-line triazole, did not exhibit a higher risk of subsequent HTD under isavuconazole therapy.